

SPENCER CHENG, PHARM.D, MS, RPH

San Francisco, CA | spencerjanecheng@gmail.com | +1-619-850-1615 | [linkedin.com/in/spencerjanecheng](https://www.linkedin.com/in/spencerjanecheng)

Highly motivated health economist with graduate training from the CHOICE Institute at the University of Washington. Diverse experiences spanning the pharmaceutical industry, academia, and consulting. Dedicated to synthesizing and effectively communicating impactful RWE studies, economic models, addressing health inequities and health policy research, and collaborating cross-functionally as a team player.

HEOR INDUSTRY EXPERIENCE

Genentech, South San Francisco, CA

Postdoctoral HEOR Fellow | Jul 2023 - present

- **RWE:** Lead and support study design, analysis, KOL engagement, and internal and external results dissemination of 4+ real-world evidence studies using various large data sources (Flatiron, SEER-Medicare, VHA warehouse) to evaluate patient characteristics, treatment patterns, clinical outcomes, and racial differences in multiple oncology indications
- **Health equity:** Lead 2 health equity focused reviews in liver cancer care, in partnership with the patient advocacy team and KOLs to increase and identify strategic engagement opportunities for our field medical teams
- **Modeling:** Partner with modeling team to develop and update a cost calculator, budget impact model, and cost-effectiveness model for congresses, and access and field team use
- **Health policy:** Conducted a thematic analysis characterizing caregiver spillover in US value assessments to support health policy team initiatives related to IRA Medicare drug pricing negotiations
- **Field and payer tools:** Developed and presented 4 HEOR educational resources to the field medical and employer account teams to support contracting and engagements with HCPs, health plans, and health care systems

VeriTech (now Curta Inc.), Seattle, WA

HEOR Research Associate | Oct 2021 - Jul 2022

- Identified strategic needs and developed research proposals to fulfill evidence gap in support of launch activities
- Completed and published a targeted literature review on health care costs and resource utilization in hemophilia A to demonstrate high economic burden of illness
- Led project management with internal colleagues, client, and vendors to meet publication goals and deadlines

Neurocrine Biosciences, San Diego, CA

Global HEOR Intern | Jun 2021 - Aug 2021

- Completed a retrospective claims database analysis to demonstrate healthcare resource utilization and prescribing practices in Huntington's Disease, and identify strategic opportunities for internal stakeholders
- Performed a targeted literature review on mapping patient reported outcomes to inform and provide project directions for the HEOR team
- Led cross-functional journal club and conducted targeted literature reviews for various research questions to support HEOR team members

HEOR ACADEMIA EXPERIENCE

University of Washington, CHOICE Institute

Postdoctoral HEOR Fellow | Jul 2022 - Jun 2023

- Completed a retrospective cohort study using claims data to estimate workplace productivity loss among patients newly diagnosed with hepatocellular carcinoma in the US
- Conducted systematic literature reviews on structured-health data algorithms to identify colorectal cancer recurrence and health-state utilities in first-line hepatocellular carcinoma
- Programmed a Markov Model to evaluate the cost-effectiveness of atezolizumab and bevacizumab combo therapy versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma adapted from a previously published model
- Developed and taught introductory programming lecture to graduate students with a focus on cohort building and analyses in a large claims dataset
- Assisted with curriculum development and lecture creation for a data science degree option for HEOR PhD students

University of Washington School of Pharmacy

Teaching Assistant, Student Researcher | Sep 2018 - Jun 2022

- Served as TA for "Introduction to Pharmacoeconomics" for 30+ students enrolled in the PharmD program
- Constructed a decision-tree model to evaluate the cost-effectiveness of a new class of medications in the treatment of chronic insomnia
- Developed and presented 4 drug monographs with budget impact models and formulary recommendations to P&T committees for student competitions and projects, won 2nd place in the Annual Local AMCP P&T competition

EDUCATION

University of Washington | 2023

MS, Health Economics and Outcomes Research

University of Washington | 2022

Doctor of Pharmacy (PharmD)

University of California, Davis |

2016

BS, Neurobiology, Physiology, and Behavior

SKILLS & PROFICIENCIES

Software Languages: R, SAS, SQL

Datasets: Flatiron, MarketScan, SEER-Medicare, VHA

Economic Modeling: Budget impact, cost calculator, cost-effectiveness

RWE Analyses: absenteeism, burden of illness, clinical outcomes, healthcare resource utilization, treatment patterns

Other: patient reported outcomes, presentations, project management, cross-functional collaboration

OTHER PHARMACEUTICAL INDUSTRY EXPERIENCE

Xcenda (now Cencora), Carrollton, TX

HEOR / Market Access Extern | Sep 2021 - Oct 2021

- Completed a product and disease state analysis, including an overview of diffuse large B-cell lymphoma therapies to support strategic project recommendations for new business development
- Conducted an ICER landscape assessment for a novel gene therapy to guide engagement strategies by manufacturers and evaluate the impact on the final evidence report
- Developed a commercial landscape assessment to assist with the selection of indications for a new infectious disease therapy

BAR Advisors, San Diego, CA

Market Access Analyst | Sep 2020 - Jun 2021

- Delivered market research on 505(b)(2) regulatory pathway analogues to guide new drug pricing decisions
- Conducted a pricing and coverage landscape analysis to provide market access recommendations for a new cardiovascular therapy
- Assisted in the selection of specialty pharmacy and HUB service providers for a biotechnology company preparing for launch
- Synthesized ad hoc market research to answer pricing and reimbursement questions for various client projects

Amgen, Thousand Oaks, CA

Global Medical Communications Intern | Jun 2020 - Sep 2020

- Synthesized a global cardiovascular disease burden deck with the inclusion of broader value elements, including societal and economic burden, for field team utilization
- Developed a training guide for the cardiovascular and bone disease medical communication teams to utilize in the launch of an internal value and access initiative

PUBLICATIONS & POSTERS

Manuscripts

Li, D., Wilson Woods, A., Luong, A., **Cheng, S.**, Tan, A. Why Liver Cancer Hits Home: Bridging Healthcare Disparities in the Asian American and Pacific Islander Community. [Planned submission March 2024]

Cheng SJ, Bansal, A, Veenstra, DL. Productivity Loss by Cancer Stage in Patients Newly Diagnosed with Hepatocellular Carcinoma: A Claims Database Analysis. [Accepted to Journal of Managed Care and Specialty Pharmacy in February 2024, awaiting citation].

Chen Y, **Cheng SJ**, Thornhill T, Solari P, Sullivan SD. Health care costs and resource use of managing hemophilia A: A targeted literature review. *J Manag Care Spec Pharm.* 2023;29(6):647-658. doi:10.18553/jmcp.2023.29.6.647

Lee W, **Cheng SJ**, Grant SJ, Marcum ZA, Devine B. Use of geriatric assessment in cancer clinical trials: A systematic review. *J Geriatr Oncol.* 2022;13(7):907-913. doi:10.1016/j.jgo.2022.04.014

Posters

Maithal, S., Tan, A., Wang, R. Hernandez, S., **Cheng, S.**, Ogale, S. Prognostic Significance of Real-World (RW) Recurrence Patterns after Resection or Ablation in Early-Stage Hepatocellular Carcinoma (HCC): Insights from the US Medicare Population. [Submitted to ASCO Annual Meeting, May 31- Jun 4, 2024, Chicago, IL.]

Cheng, S., Tan, A. Are we closing the gap? A review of health equity focused interventions along the liver cancer care cascade in the US. [Submitted to ISPOR Annual Meeting, May 5 - May 8, 2024, Atlanta, GA.]

Cheng, S., Pandey, R., Kang, A., Kowal, S. Understanding the disconnect: Characterizing trends in inclusion of family and informal caregiver spillover in US value assessments. [Submitted to ISPOR Annual Meeting, May 5 - May 8, 2024, Atlanta, GA.]

Cheng, S., Bansal, A., Veenstra, D. Defining colorectal cancer recurrence with structured-health data algorithms: A targeted literature review. ISPOR Annual Meeting, May 7 - 10, 2023, Boston, MA.

Cheng, S., Farrar, M., Franey, E., Sen, G. Treatment and Prescription Patterns in Patients with Huntington Disease: Results from a Real-World Claims Analysis. Huntington Study Group Annual Meeting (virtual, November 4 - 6, 2021). [Abstract published in The Journal of Huntington's Disease].

Cheng, S., Veenstra, D. Cost-Effectiveness Analysis of Suvorexant in the Treatment of Adults with Primary Chronic Insomnia. Academy of Managed Care Pharmacy Annual Meeting (virtual, April 12 - 16, 2021).

Cheng, S., Duong, A. Characterization of Oral Chemotherapy Prescribing and Management in an Outpatient Neuro-Oncology Clinic. American Society of Health System Pharmacists Midyear Clinical Meeting (virtual, December 6 - 10, 2020).